One-year access to more than 500 world journals available in the system
-
http://medilib.ir
- Duration of Time : 365 Day
Price : 300$- Special Price : 100$
The Purdue Pharma Opioid Settlement — Accountability, or Just the Cost of Doing Business?
Corey S. Davis, J.D., M.S.P.H.
doi : 10.1056/NEJMp2033382
N Engl J Med 2021; 384:97-99
Drug-Coated Devices for Peripheral Arterial Disease
Andrew Farb, M.D., Misti Malone, Ph.D., and William H. Maisel, M.D., M.P.H.
doi : 10.1056/NEJMp2031360
N Engl J Med 2021; 384:99-101
Doctor as Street-Level Bureaucrat
Elvin H. Geng, M.D., M.P.H.
doi : 10.1056/NEJMp2019939
N Engl J Med 2021; 384:101-103
Placebo-Controlled Trials of Covid-19 Vaccines — Why We Still Need Them
doi : 10.1056/NEJMp2033538
N Engl J Med 2021; 384:e2
Cardiac Myosin Activation with Omecamtiv Mecarbil in Systolic Heart Failure
John R. Teerlink, M.D., Rafael Diaz, M.D., G. Michael Felker, M.D., M.H.S., John J.V. McMurray, M.D., Marco Metra, M.D., Scott D. Solomon, M.D., Kirkwood F. Adams, M.D., Inder Anand, M.D., D.Phil., Alexandra Arias-Mendoza, M.D., Tor Biering-S?rensen, M.D., Michael B?hm, M.D., Diana Bonderman, M.D.,
doi : 10.1056/NEJMoa2025797
N Engl J Med 2021; 384:105-116
The selective cardiac myosin activator omecamtiv mecarbil has been shown to improve cardiac function in patients with heart failure with a reduced ejection fraction. Its effect on cardiovascular outcomes is unknown.
Sotagliflozin in Patients with Diabetes and Recent Worsening Heart Failure
Deepak L. Bhatt, M.D., M.P.H., Michael Szarek, Ph.D., P. Gabriel Steg, M.D., Christopher P. Cannon, M.D., Lawrence A. Leiter, M.D., Darren K. McGuire, M.D., M.H.Sc., Julia B. Lewis, M.D., Matthew C. Riddle, M.D., Adriaan A. Voors, M.D., Ph.D., Marco Metra, M.D., Lars H. Lund, M.D., Ph.D., Michel Komajda, M.D.,
doi : 10.1056/NEJMoa2030183
N Engl J Med 2021; 384:117-128
Sodium–glucose cotransporter 2 (SGLT2) inhibitors reduce the risk of hospitalization for heart failure or death from cardiovascular causes among patients with stable heart failure. However, the safety and efficacy of SGLT2 inhibitors when initiated soon after an episode of decompensated heart failure are unknown.
Sotagliflozin in Patients with Diabetes and Chronic Kidney Disease
Deepak L. Bhatt, M.D., M.P.H., Michael Szarek, Ph.D., Bertram Pitt, M.D., Christopher P. Cannon, M.D., Lawrence A. Leiter, M.D., Darren K. McGuire, M.D., M.H.Sc., Julia B. Lewis, M.D., Matthew C. Riddle, M.D., Silvio E. Inzucchi, M.D., Mikhail N. Kosiborod, M.D., David Z.I. Cherney, M.D., Ph.D., Jamie P. Dwyer, M.D.,
doi : 10.1056/NEJMoa2030186
N Engl J Med 2021; 384:129-139
The efficacy and safety of sodium–glucose cotransporter 2 inhibitors such as sotagliflozin in preventing cardiovascular events in patients with diabetes with chronic kidney disease with or without albuminuria have not been well studied.
Bupropion and Naltrexone in Methamphetamine Use Disorder
Madhukar H. Trivedi, M.D., Robrina Walker, Ph.D., Walter Ling, M.D., Adriane dela Cruz, M.D., Ph.D., Gaurav Sharma, Ph.D., Thomas Carmody, Ph.D., Udi E. Ghitza, Ph.D., Aimee Wahle, M.S., Mora Kim, M.P.H., Kathy Shores-Wilson, Ph.D., Steven Sparenborg, Ph.D., Phillip Coffin, M.D., M.I.A.,
doi : 10.1056/NEJMoa2020214
N Engl J Med 2021; 384:140-153
The use of naltrexone plus bupropion to treat methamphetamine use disorder has not been well studied.
Ewing’s Sarcoma
Nicol? Riggi, M.D., Ph.D., Mario L. Suvà, M.D., Ph.D., and Ivan Stamenkovic, M.D.
doi : 10.1056/NEJMra2028910
N Engl J Med 2021; 384:154-164
Placement of an External Ventricular Drain
Rimal H. Dossani, M.D., Devi P. Patra, M.D., Danielle L. Terrell, M.D., and Brian Willis, M.D.
doi : 10.1056/NEJMvcm1805314
N Engl J Med 2021; 384:e3
Primary Adrenal Lymphoma
Tara McDonnell, M.B., B.Ch., B.A.O., and Eamon Mulkerrin, M.B., B.Ch., B.A.O.
doi : 10.1056/NEJMicm2017821
N Engl J Med 2021; 384:165
Left Ventricular Rupture
?yvind H. Lie, M.D., Ph.D., and Ketil Lunde, M.D., Ph.D.
doi : 10.1056/NEJMicm2020871
N Engl J Med 2021; 384:e4
Case 1-2021: A 76-Year-Old Woman with Lethargy and Altered Mental Status
Lisa M. Bebell, M.D., R. Gilberto Gonzalez, M.D., Ph.D., Amy K. Barczak, M.D., and Melis N. Anahtar, M.D., Ph.D.
doi : 10.1056/NEJMcpc2027084
N Engl J Med 2021; 384:166-176
Stimulation of Contractility in Systolic Heart Failure
Karl Swedberg, M.D., Ph.D.
doi : 10.1056/NEJMe2033311
N Engl J Med 2021; 384:178-179
Cardioprotection with Yet Another SGLT2 Inhibitor — An Embarrassment of Riches
Frank C. Brosius, M.D., and Per O. Vandvik, M.D., Ph.D.
doi : 10.1056/NEJMe2033176
N Engl J Med 2021; 384:179-181
Audio Interview: Covid-19 in South Africa and a New SARS-CoV-2 Variant
Eric J. Rubin, M.D., Ph.D., Lindsey R. Baden, M.D., Salim S. Abdool Karim, M.B., Ch.B., Ph.D., and Stephen Morrissey, Ph.D.
doi : 10.1056/NEJMe2100736
N Engl J Med 2021; 384:e14
Spinal Cord Injury — Healing from Within
Michelle Monje, M.D., Ph.D.
doi : 10.1056/NEJMcibr2030836
N Engl J Med 2021; 384:182-184
Distribution of KRASG12C Somatic Mutations across Race, Sex, and Cancer Type
doi : 10.1056/NEJMc2030638
N Engl J Med 2021; 384:185-187
Neutralizing Antibody LY-CoV555 for Outpatient Covid-19
doi : 10.1056/NEJMc2033787
N Engl J Med 2021; 384:189
Hydroxychloroquine with or without Azithromycin in Covid-19
doi : 10.1056/NEJMc2031780
N Engl J Med 2021; 384:190-191
Vaccinating Detained Migrants against SARS-CoV-2 — Preventing Another Tragedy
Carlo Foppiano Palacios, M.D., and Mark A. Travassos, M.D.
doi : 10.1056/NEJMpv2035416
N Engl J Med 2021; 384:e5
Business Not as Usual — Covid-19 Vaccination in Persons with Substance Use Disorders
Joshua A. Barocas, M.D.
doi : 10.1056/NEJMpv2035709
N Engl J Med 2021; 384:e6
